ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.08B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.89M
Average 1.66M
ACAD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
ACADIA Pharmaceuticals Inc.NASDAQ: ACAD
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow dips below year-ago levels
Q2 FY2026 financing cash flow of $14.73M fell 7.7% year over year, behind the +154.8% change in trailing-twelve-month financing cash flow. Sequentially, it rose 248.0% from the prior quarter. Over 3 fiscal years it compounded at +82.6% a year.
Context
- Financing cash flow amounted to 4.7% of revenue in FY2025, up 3.9 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.7% toward the trailing-twelve-month pace of +154.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 49.88M USD
- Year-over-year change
- +628.8%
- 4-year CAGR
- +28.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.88M | +628.8% |
| FY2024 | 2024-12-31 | 6.85M | -72.8% |
| FY2023 | 2023-12-31 | 25.13M | +206.5% |
| FY2022 | 2022-12-31 | 8.2M | -54.9% |
| FY2021 | 2021-12-31 | 18.16M | — |
Financing Cash Flow vs competitors
How ACAD compares with its peers on the latest reported figures
- ACAD's LTM Jun 2026 financing cash flow of $51.05M is the 9th largest of the 11 companies compared; the peer median is $139.34M.
- Its year-over-year change of +154.8% is the 6th highest of 10, against a peer median of +256.9%.
- Financing cash flow amounts to 4.5% of revenue for ACAD, versus a peer median of 11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.23B | +505.2% | +306.4% | — | |
| LTM Mar 2026 | $463.02M | +23881.0% | +141.9% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $396.39M | — | +136.2% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $271.31M | +71.7% | +89.7% | 1356.6% |
| LTM Mar 2026 | $165.89M | +1517.0% | +11.1% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $112.79M | +3.6% | — | — |
| LTM Jun 2026 | $88.79M | -18.1% | -29.1% | 11.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $87.96M | +345.2% | -12.7% | — |
| LTM Jun 2026 | $51.05M | +154.8% | +82.6% | 4.5% | |
| LTM Dec 2025 | $45.05M | +256.9% | -23.8% | — | |
| LTM Mar 2026 | $2.36M | +59.4% | — | 1.1% | |
| Peer median (excluding ACAD) | $139.34M | +256.9% | +50.4% | 11.4% | |
Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (249.88M) |
| Stock-Based Compensation | 63.62M | 68.2M | 66.42M | 67.05M | 0 |
| Change in Working Capital | (24.82M) | 37.99M | 18.13M | 4.16M | (89.76M) |
| Accounts Receivables | (16.12M) | 2.26M | (39.27M) | (2.35M) | (43.54M) |
| Inventory | (4.21M) | 2.42M | (28.81M) | (49.55M) | (18.2M) |
| Accounts Payables | (1.62M) | 5.87M | 4.8M | (1.35M) | (5.29M) |
| Other Working Capital | (2.88M) | 27.44M | 81.41M | 57.4M | (22.73M) |
| Other Non-Cash Items | 75K | (6.28M) | (12.12M) | (155.82M) | 46.71M |
| Operating Cash Flow | (125.66M) | (114.04M) | 16.7M | 157.72M | 109.84M |
| Capital Expenditures | (1.12M) | 0 | (40.05M) | (523K) | (4.69M) |
| Acquisitions (Net) | 69.98M | 0 | (32.05M) | 0 | 0 |
| Purchases of Investments | (492.8M) | (363.17M) | (369.99M) | (505.1M) | (692.57M) |
| Sales of Investments | 422.82M | 436.42M | 442.03M | 328.57M | 493.53M |
| Other Investing Activities | (69.98M) | 0 | 32.05M | 146.52M | 0 |
| Investing Cash Flow | (71.1M) | 73.24M | 32M | (30.54M) | (302.56M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Effect of Forex Changes | 7K | 6K | (18K) | (94K) | 951K |
| Net Change in Cash | (178.59M) | (32.59M) | 73.81M | 133.93M | (141.89M) |
| Free Cash Flow | (126.78M) | (114.04M) | (23.35M) | 157.2M | 105.15M |
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.